Endosense is developing a catheter ablation treatment for cardiac rhythm disorders, including atrial fibrillation (AF). AF is the most common cardiac rhythm disorder today, affecting more than six million people worldwide.
Currently, most AF patients are treated with ineffective and side effect-causing drugs, with the primary alternative being invasive ablation surgery. Endosense is developing a minimally invasive treatment option that is safe and effective.
Endosense’s flagship product, the TactiCath, is the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during a catheter ablation procedure. TactiCath has undergone extensive preclinical testing in the U.S. and Europe. The company’s first human trial is slated to occur in mid-2008, with CE Mark approval expected in 2009. In the U.S., TactiCath is limited to investigational use only.
The company was founded in 2003 by Dr. Vitali Verin, an accomplished interventional cardiologist based in Geneva.